SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant downward pressure following the announcement of a proposed $1 billion convertible senior notes offering, which has sparked investor frustration over potential dilution and the timing of the capital raise. While community sentiment remains polarized, many long-term shareholders are debating whether this financing is a strategic move to accelerate satellite deployment and vertical integration or a signal of unexpected financial strain after management previously indicated the company was sufficiently funded.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

Atai Life Sciences is currently trending amid reports that Eli Lilly is in advanced talks for a potential acquisition, fueling significant community excitement regarding a possible premium valuation. Investors are closely monitoring clinical trial milestones and potential M&A activity, with discussions centered on whether the company's mental health pipeline will trigger a bidding war or secure a long-term premium buyout.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is trending as markets digest reports of foundry price hikes across advanced nodes, signaling sustained pricing power amidst tight global chip capacity. Investors are closely monitoring how this move affects the broader semiconductor ecosystem as they look ahead to upcoming earnings and critical monthly revenue disclosures.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending ahead of a pivotal July 29 FDA advisory committee meeting for its Duchenne muscular dystrophy therapy, Deramiocel. Investors and the community are actively debating potential regulatory hurdles, including data integrity questions raised in media reports, while maintaining a strong focus on the company's long-term HOPE-3 data and upcoming legal developments regarding commercialization rights.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently trending following reports of an unsolicited $53 billion takeover bid from Stripe and Advent International at $60.50 per share, triggering significant options volatility and debate over whether the offer undervalues the company. Investors are actively discussing the possibility of a higher counter-offer or a potential bidding war, as many long-term shareholders view the proposed price as a lowball attempt to capitalize on recent depressed valuations.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as the clinical stage company recently announced positive 26-week durability results for its Phase 3 COMP360 trial, fueling community optimism about its potential for FDA approval. Investors are actively discussing the sector's regulatory momentum and the strategic implications of a potential acquisition of major shareholder Atai Life Sciences by Eli Lilly.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending following a significant stock price decline driven by the pricing of a $125 million convertible note offering, which has sparked intense debate among retail investors regarding dilution risks versus the company's need for capital to fund multi-billion dollar data center projects. While some community members express frustration over management's financing strategy and lack of institutional ownership, others maintain a bullish stance, arguing that the capital is essential for project execution and highlighting the potential for a short squeeze given the elevated short interest.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is experiencing heightened volatility as investors grapple with the broader semiconductor sector's correction, with the stock drawing significant attention from traders debating the sustainability of its 'trillion-dollar' valuation versus potential long-term AI infrastructure leadership. The conversation is currently split between bulls betting on the stock's role in custom silicon and AI networking, and bears pointing to recent price pullbacks as evidence of an overheated hype cycle.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing significant volatility as investors weigh the cooling inflation outlook against geopolitical instability and concerns regarding overcapacity in AI data center infrastructure. The community remains deeply divided, with many traders aggressively buying dips in anticipation of a rebound, while others warn of a broader cyclical correction in the semiconductor sector.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as investors focus on its strong positioning within the hyperscaler AI infrastructure race and positive institutional sentiment ahead of upcoming earnings. The community is actively discussing its technical breakout potential, the impact of AI cloud expansion, and broader market rotations into high-quality tech leaders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin...

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting PR...

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides...

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and...

Citius Oncology Ships First International Order of LYMPHIR to Europe

Citius Oncology Ships First International Order of LYMPHIR to Europe Citius Oncology Ships First International Order of LYMPHIR to Europe PR Newswire CRANFORD, N.J., April 29, 2026 Order fulfilment expands international patient access to LYMPHIR following initial U.S. launchDistribution by regional...

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces Closing of Registered Direct Offering of...

What's Behind The Drop In Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after it announced a registered direct offering, raising dilution concerns.read more...

Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced...

Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development

Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting...

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts PR Newswire CRANFORD...

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.

Citius Pharmaceuticals Inc

Neutral Sentiment

$100+

$80 - $99.99

$70 - $79.99

$60 - $69.99

Stripe and private equity firm Advent International just submitted a joint takeover offer for PayPal ($PYPL) at $60.50 per share, valuing the company at more than $53 billion - a roughly 28% premium to Tuesday's close. What do you think PayPal is really worth? Cast your vote and explain your reasoning in the comments.

What should PayPal ($PYPL) be worth in a takeover deal?

Current Price	$0.5311
Prev Close	$0.532
Open	$0.5236
Dividend Yield	0.00%
50-Day Moving Average	$0.60
Beta	1.47
Avg. Volume	272,553.53
PE Ratio	-0.21

52-Week High	$2.19
52-Week Low	$0.476
Market Capitalization	$14.6M
EPS (Annual)	-$3.38
Price to Book	0.19
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CTXRCitius Pharmaceuticals Inc

Latest CTXR News